Regeneron Antibody Cocktail Is First FDA-Approved Ebola Treatment
October 14 2020 - 6:40PM
Dow Jones News
By Josh Beckerman
A Regeneron Pharmaceuticals Inc. antibody cocktail has become
the first treatment for the Ebola virus approved by the U.S. Food
and Drug Administration.
The treatment, Inmazeb, is also known as REGN-EB3. It includes
atoltivimab, maftivimab and odesivimab-ebgn.
The FDA said "today's action demonstrates the FDA's ongoing
commitment to responding to public health threats--both
domestically and abroad--on the basis of science and data."
Regeneron shares were up 0.6% after hours at $604.62.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 14, 2020 18:25 ET (22:25 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2024 to May 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From May 2023 to May 2024
